We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CureVac NV | NASDAQ:CVAC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 2.26% | 2.71 | 2.71 | 2.72 | 2.725 | 2.61 | 2.69 | 183,021 | 19:57:02 |
From May 2022 to May 2024
By Jaime Llinares Taboada
CureVac NV said Tuesday that it has filed a patent infringement lawsuit in a German court against BioNTech SE.
The Nasdaq-listed biopharmaceutical company said the lawsuit seeks fair compensation for infringement of a portfolio of CureVac's intellectual property rights which are used in BioNTech and Pfizer Ltd.'s mRNA COVID-19 vaccine.
CureVac said its IP portfolio protects inventions essential to the design and development of BioNTech's vaccine.
"Accordingly, CureVac's intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life saving medicines," the company said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
July 05, 2022 07:46 ET (11:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year CureVac NV Chart |
1 Month CureVac NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
